Agenus Inc. (NASDAQ:AGEN) Receives $10.50 Consensus Target Price from Analysts

Agenus Inc. (NASDAQ:AGEN) has earned a consensus recommendation of “Hold” from the six ratings firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.50.

Several equities research analysts have recently weighed in on the stock. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. B. Riley decreased their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Jefferies Financial Group restated a “hold” rating and issued a $7.00 target price (up from $3.00) on shares of Agenus in a research note on Friday, July 19th. Finally, HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and lowered their target price for the company from $40.00 to $9.00 in a research note on Thursday, July 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AGEN. Vanguard Group Inc. raised its holdings in shares of Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Agenus by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Agenus by 81.3% during the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 84,477 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Trading Up 1.1 %

Shares of NASDAQ:AGEN opened at $4.46 on Friday. The company has a market capitalization of $93.66 million, a price-to-earnings ratio of -0.35 and a beta of 1.37. Agenus has a 12 month low of $4.18 and a 12 month high of $19.69. The firm’s 50-day moving average is $5.09 and its 200 day moving average is $9.05.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same period last year, the business posted ($4.00) earnings per share. As a group, equities analysts forecast that Agenus will post -10.87 EPS for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.